ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 791,79
0,64%
Dow Jones
42 385,12
0,50%
DAX
19 473,63
1,32%
Brent Oil
71,645
0,98%
Bitcoin
66 296,69
1,71%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Travere Therapeutics Inc (TVTX)

  7. Travere Therapeutics Inc (TVTX) Actualités

TVTX

Travere Therapeutics (TVTX)

Travere Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:TVTX
DateHeureSourceTitreSymboleSociété
26/09/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
26/09/202422h01GlobeNewswire Inc.Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-UpNASDAQ:TVTXTravere Therapeutics Inc
12/09/202423h00GlobeNewswire Inc.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TVTXTravere Therapeutics Inc
12/09/202400h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TVTXTravere Therapeutics Inc
10/09/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
10/09/202422h01GlobeNewswire Inc.Travere Therapeutics to Present at the 2024 Cantor Global Healthcare ConferenceNASDAQ:TVTXTravere Therapeutics Inc
05/09/202423h34GlobeNewswire Inc.Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
22/08/202422h30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024NASDAQ:TVTXTravere Therapeutics Inc
06/08/202422h30GlobeNewswire Inc.Travere Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:TVTXTravere Therapeutics Inc
01/08/202423h24Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:TVTXTravere Therapeutics Inc
01/08/202422h40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TVTXTravere Therapeutics Inc
01/08/202422h01GlobeNewswire Inc.Travere Therapeutics Reports Second Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
25/07/202422h30GlobeNewswire Inc.Travere Therapeutics to Report Second Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
08/07/202422h30GlobeNewswire Inc.Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual ConferenceNASDAQ:TVTXTravere Therapeutics Inc
14/06/202422h05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TVTXTravere Therapeutics Inc
09/05/202422h30GlobeNewswire Inc.Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association CongressNASDAQ:TVTXTravere Therapeutics Inc
06/05/202422h01GlobeNewswire Inc.Travere Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
29/04/202422h30GlobeNewswire Inc.Travere Therapeutics to Report First Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
24/04/202413h05GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
24/04/202409h00PR Newswire (Canada)CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
04/04/202422h30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians InternationalNASDAQ:TVTXTravere Therapeutics Inc
03/04/202422h30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses AssociationNASDAQ:TVTXTravere Therapeutics Inc
11/03/202412h05GlobeNewswire Inc.Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)NASDAQ:TVTXTravere Therapeutics Inc
23/02/202413h05GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
23/02/202408h00PR Newswire (US)CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathyNASDAQ:TVTXTravere Therapeutics Inc
20/02/202414h10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TVTXTravere Therapeutics Inc
15/02/202422h01GlobeNewswire Inc.Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
14/02/202420h35Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TVTXTravere Therapeutics Inc
08/02/202422h30GlobeNewswire Inc.Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
01/02/202422h30GlobeNewswire Inc.Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:TVTXTravere Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TVTX

Dernières Valeurs Consultées

NASDAQ
AAWPHXX
Morgan Stanley Finance L...
TG
QOL
Sol
LSE
AI13
Citi Fun 25
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés